Market Press Release – May 13, 2011 12:58 pm – New Delhi, May 13, 2011: Cancer cervix is the commonest cancer among Indian women, every hour it kills almost eight Indian women. It is caused by HPV infection, a common sexually transmitted viral infection. The high risk cofactors in its carcinogenesis are multiple sex partners, early age of marriage and intercourse, low socio-economic status, herpes simplex virus and human immunodeficiency virus (HIV) infection, smoking, dietary deficiency and use of oral contraceptives etc.
Dr. Suversha Khanna, the Director of premier cancer hospital in Delhi and NCR; commented that, cancer cervix is the commonest cancer among women cancer patients being registered for cancer treatment in Dharamshila hospital every year. Around 100,000 new cases of cancer cervix are diagnosed, and 74000 die due to it, every year in our country. India is home for more than 20% of total new cases diagnosed in world. Though it progresses at a very slow speed and preceded by an well established and easily identifiable precancerous stage; called Cervical Intraepithelial Neoplasia( CIN), > 2/3rd ladies with cancer cervix present in advanced stages (stage 2 or more), when its prognosis is not so good.
Dr (Mrs) Kamlesh Mishra, Senior Consulant Gynecolgoy Oncology and Gynecological ; comments that it takes about two or three decades before an HPV infection gets transformed into frank cancer. Hence, it can be diagnosed in easily treatable precancerous stages( CIN 1/2/3) with Pap’s smear.
[Note from SaneVax: The SaneVax Team would like to express their thanks to the health officials at Dharamshila Cancer Hospital for recognizing the safest cervical cancer prevention method available to date, adequate screening and follow-up. No mention in this article of unproven HPV vaccination programmes.
SaneVax members are pleased to see health professionals who care more about the health and survival of their patients than promoting a vaccination agenda which may or may not work, particularly when there is no adequate means available to monitor HPV vaccine efficacy.
The SaneVax Team believes until such time as there is a method for medical professionals and consumers to monitor HPV vaccine efficacy that includes DNA sequencing – HPV vaccines should not be on the market.]